Ceftizoxime
This article needs additional citations for verification. (April 2013) (Learn how and when to remove this template message) |
{{Drugbox | IUPAC_name = (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | image = ceftizoxime.png
| tradename = Cefizox | Drugs.com = Consumer Drug Information | MedlinePlus = a684043 | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
| CAS_number = 68401-81-0
| CAS_supplemental = 68401-82-1
| ATC_prefix = J01
| ATC_suffix = DD07
| PubChem = 6533629
| DrugBank =
| ChemSpiderID = 5018818
| UNII_Ref = 
| UNII = C43C467DPE
| KEGG = D07658
| ChEMBL = 528
| C=13 | H=13 | N=5 | O=5 | S=2 | molecular_weight = 383.405 g/mol }}
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ceftizoxime is a third-generation cephalosporin available for parenteral administration.
Unlike other 3rd generation cephalosporins, in ceftizoxime the whole C-3 side chain has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subjected to metabolism.
Category
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages